Prof. Charles McKenna

University of Southern California, Los Angeles, U.S.A.
Development of peptidomimetic prodrugs, study of their antiviral activities and pharmacokinetic parameters. Investigation of oral bioavailability of active prodrugs in animal models.

 

Prof. Graciela Andrei, Prof. Robert Snoeck, Prof. Johan Neyts, Prof. Jan Balzarini

Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium
Antiviral screening.

 

Dr. Tomáš Cihlář

Gilead Sciences, Inc., Foster City, California, U.S.A.
Biological activity screening, pharmacokinetic profiles of active compounds and mutual general cooperation within Gilead Sciences & IOCB Research Centre.

 

Dr. Luke Guddat

The School of Chemistry and Molecular Biosciences, The University of Queensland, Brisbane, 4072 QLD, Australia
Antimalarial program.

 

Dr. Helena Mertlíková-Kaiserová, Dr. Ivan Votruba

IOCB Prague
Cytostatic activity, inhibitory activity towards thymidine phosphorylase.

 

Dr. Zdeněk Zídek

Institute of Experimental Medicine, Academy of Sciences of the Czech Republic
Immunomodulatory activity of compounds.

 

Dr. Radek Pohl, Dr. Martin Dračínský

IOCB Prague
NMR spectroscopy.